Cardium Launches New AWARE Clinical Stu...(linical Trial CenterCincinnati; North Oh...)

Date:6/11/2008

linical Trial Center, Cincinnati; North Ohio Heart Center, Elria); Oklahoma (Oklahoma Cardiovascular Research Group, Inc., Oklahoma City); Oregon (Providence Heart & Vascular Institute, Portland); Pennsylvania (Geisinger Clinic, Danville; Heritage Cardiology Associates, Camp Hill); Rhode Island (The Miriam Hospital, Providence); Tennessee (Meharry Medical College, Nashville; The Stern Cardiovascular Center, Germantown); Texas (Baylor University Medical Center, Dallas; Baylor College of Medicine, Houston; Cardiovascular Associates of East Texas, Tyler; South Texas Cardiovascular Consultants, San Antonio); Vermont (Fletcher Allen Health Care, Burlington); Washington (Swedish Heart and Vascular Clinic, Seattle); and Wisconsin (Care Foundation, Wausau).

About Women and Heart Disease

An estimated 7.3 million American women are currently living with coronary heart disease. Of these, approximately 4.6 million American women suffer from angina and it is estimated that approximately 300,000 women will die annually from coronary heart disease. The American Heart Association reports that more women's lives are claimed annually by cardiovascular disease than by the next five leading causes of death combined (all cancers, chronic obstructive pulmonary disease (COPD), Alzheimer's, diabetes and accidents). Despite these stark statistics, surveys indicate that nearly half of women are not aware that heart disease is the leading cause of death among women, and only 20 percent were aware that heart disease as the greatest health problem facing women today. Observed differences between men and women with coronary heart disease are not fully understood. Some researchers believe the differences may be the result of microvascular disease, the narrowing or stiffening of the smaller arteries and arterioles that nourish the heart. While microvascular disease is believed to affect both men and women with coronary heart disease, the prevalence is higher in women and in patients
'/>"/>

SOURCE Cardium Therapeutics Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. Cardium Completes $5.3 Million Registered Direct Offering
3. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
4. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
5. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
6. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
7. Cardium Reports on First Quarter 2008 Highlights and Financial Results
8. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
9. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
10. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
11. Novozymes Launches Enzyme to Reduce Acrylamide in Food